Stereotactic ablative radiotherapy compared with VATS L-MLND for stage I NSCLC
Prof. Joe Chang
The revised STARS study at MD Anderson Cancer Center (Houston, TX) investigated outcomes of patients with operable early-stage non-small cell lung cancer after stereotactic ablative radiotherapy (SABR), with prespecified comparison with outcomes of a contemporary cohort of patients who underwent video-assisted thoracoscopic surgical lobectomy with mediastinal lymph node dissection (VATS L-MLND). Long-term survival after SABR was non-inferior to long-term survival after VATS L-MLND.
